Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare neurological disorder that affects the peripheral nerves and is characterized by gradually increasing sensory loss and weakness associated with loss of reflexes. CIDP is caused by damage to the covering of the nerves, called myelin, and can start at any age, but is more frequent in men than women. The exact cause of CIDP is unknown, but there are strong indications that it is an autoimmune disorder, where the bodys natural defenses attack healthy tissue. CIDP is closely related to Guillain-Barre syndrome (GBS), but while GBS is generally considered more of an acute, or short-term, disease, CIDP is considered a chronic, or long-term, disease.

Symptoms of CIDP include tingling or no feeling in fingers and toes, weakness of arms and legs, loss of deep tendon (muscle stretch) reflexes, fatigue or feeling tired, and unusual feelings in the body. CIDP can be difficult to diagnose, as its symptoms can be confused with those of GBS, and there is no test to diagnose CIDP. Healthcare providers may do other tests, such as blood and urine tests, to confirm a diagnosis. Treatment for CIDP includes the use of steroid medicine and other treatments that focus on the immune system, along with physical therapy. Many people with CIDP benefit from treatment, and one of the goals of early diagnosis and proper treatment is to avoid severe disability and improve the long-term outlook.